Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.19
Views: 1001
Rating:

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

Prof Andrew Armstrong speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about findings from the ARCHES trial looking into androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC).

Addressing the findings, Prof Armstrong reveals a 61% improvement in the hazard of death or progression with enzalutamide compared to placebo, a major difference.

He explains that the safety profile of enzalutamide is very well known due to the medication being already on the market and that there was no increased risk of death from side effects seen in the study.
 

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation